/

COLL

Collegium Pharmaceutical, Inc.After hours

22.51+0.98 +4.55%USD

NasdaqGS · as of Oct 14, 16:00 ET · 15m delayAfter hours 22.51 0.00%

Open

21.65

Prev close

21.53

Day range

21.4722.56

52-week range

21.4350.79

Volume

920.24K1.21×

Mkt cap

732.83M

P/E ttm

17.72

Fwd P/E

3.10

EPS ttm

1.27

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−55.68%

Price Chart

Yahoo Finance · delayed

COLLOct 14, 2026O 21.65H 22.56L 21.47C 22.51+0.98 (+4.55%)Vol 920.24K

SMA 5024.56
SMA 20034.66

1Y change −29.74% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

COLL Collegium Pharmaceutical, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.64%
1 month: −1.32%
3 months: −38.70%
6 months: −35.56%
Year to date: −51.38%
1 year: −30.03%

Valuation & ownership

Market cap: 732.83M
Enterprise value: 1.79B
P/E (ttm): 17.72
Forward P/E: 3.10
PEG ratio: 0.64
Price / book: 2.35
Price / sales (ttm): 0.91
EV / EBITDA: 4.42
EPS (ttm): 1.27
EPS (forward): 7.26
Beta (5y monthly): 0.73
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 32.56M
Float: 29.77M
Short % of float: 20.24%
Short ratio (days): 5.86
Held by insiders: 1.15%
Held by institutions: 130.77%
Avg volume (3m): 759.20K
50-day average: 24.83
200-day average: 34.80
52-week change: −30.03%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 44.4
vs 50-day SMA: −8.36%
vs 200-day SMA: −35.06%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.72%
Realised vol (20d, ann.): 24.1%
From 52-week high: −55.68%
From 52-week low: +5.04%

ANR

Analyst Consensus

8 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

49.00

+117.68% implied

Low 43.00Median 48.50High 60.00

Recommendation trend

Now7 / 1 / 0
1m ago7 / 1 /

DES

About Collegium Pharmaceutical, Inc.

Yahoo Finance profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 423
Headquarters: Stoughton, MA, United States
Website: collegiumpharma.com
Officers: Mr. Vikram Karnani CEO, President & Director
Ms. Colleen Tupper Executive VP & CFO

SEAS

Seasonality · COLL

2015–2026 · monthly returns

Strongest month Nov +21.24%Weakest month Mar −5.48%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.8	-9.3	-20.6	2.0	-0.4	7.7	-2.2	-30.5	-11.3	3.2			−51.4%
2025	12.1	-9.6	2.8	-9.6	7.9	1.5	1.0	29.9	-9.8	2.9	29.7	-0.8	+61.6%
2024	7.1	11.4	5.7	-4.9	-10.3	-2.8	19.8	-0.3	0.5	-11.6	-10.7	-6.1	−6.9%
2023	21.0	-5.5	-9.6	-3.0	-5.2	-2.6	5.9	2.9	-4.6	-2.6	17.8	20.1	+32.7%
2022	-4.4	9.1	4.6	-20.9	-3.0	13.4	-3.0	2.3	-8.9	12.0	21.9	6.1	+24.2%
2021	20.5	-2.3	0.5	-5.9	7.1	-1.0	5.3	-17.5	-3.8	-0.6	-10.4	6.3	−6.7%
2020	-2.3	18.1	-31.2	26.6	6.6	-20.6	-9.8	20.8	9.2	-14.4	3.7	8.3	−2.7%
2019	-6.8	9.9	-13.9	-8.0	-17.4	14.2	-16.6	5.6	-0.9	4.5	81.1	-5.3	+19.9%
2018	29.1	0.6	6.5	-7.4	-4.4	5.4	-19.2	-11.3	-13.8	8.9	19.6	-10.5	−7.0%
2017	8.0	-21.2	-24.1	-2.5	-16.2	52.2	-4.3	-16.1	4.5	-1.5	67.1	7.0	+18.6%
2016	-38.1	2.4	4.1	5.0	-12.3	-29.1	2.4	-31.3	131.2	-22.3	10.6	-6.0	−43.4%
2015						4.9	12.3	-24.5	46.2	-16.9	3.4	44.8	+61.8%

INSD

Insider Activity · COLL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

96K shares

Sells, 6 months

17.3K shares

Net shares

+78.7K

Net change in insider shares

+26.60%

Date	Insider	Transaction	Shares	Value
Jun 7, 2026	Santini GinoDirector	Conversion of Exercise of derivative security at price 16.49 per share.	8.7K	$143.46K
May 17, 2026	Freund John GordonDirector	Sale at price 34.05 per share.	20	$681
May 14, 2026	Freund John GordonDirector	Sale at price 34.54 per share.	4.1K	$142.55K
May 14, 2026	Freund John GordonDirector	Conversion of Exercise of derivative security at price 16.49 per share.	8.7K	$143.46K
May 13, 2026	Santini GinoDirector	Stock Award(Grant) at price 0.00 per share.	8.7K	—
May 13, 2026	Bohlin Garen G.Director	Stock Award(Grant) at price 0.00 per share.	8.7K	—
May 13, 2026	Freund John GordonDirector	Stock Award(Grant) at price 0.00 per share.	8.7K	—
May 13, 2026	Lurker Nancy SDirector	Stock Award(Grant) at price 0.00 per share.	8.7K	—
May 13, 2026	Paya Carlos VDirector	Stock Award(Grant) at price 0.00 per share.	8.7K	—
May 13, 2026	Balice-Gordon Rita JDirector	Stock Award(Grant) at price 0.00 per share.	8.7K	—
May 13, 2026	Donovan MichaelDirector	Stock Award(Grant) at price 0.00 per share.	17.5K	—
May 12, 2026	Lurker Nancy SDirector	Sale at price 35.97 per share.	4.5K	$161.86K
May 10, 2026	Bohlin Garen G.Director	Sale at price 37.18 per share.	8.7K	$323.49K
May 10, 2026	Bohlin Garen G.Director	Conversion of Exercise of derivative security at price 16.49 per share.	8.7K	$143.46K
Mar 17, 2026	Dieter DavidGeneral Counsel	Sale at price 34.92 per share.	14K	$488.10K
Mar 8, 2026	Dieter DavidGeneral Counsel	Sale at price 36.65 per share.	6.2K	$228.11K
Mar 2, 2026	Dreyer ScottOfficer	Sale at price 40.36 - 40.99 per share.	50K	$2.02M
Feb 9, 2026	Karnani VikramChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	111.8K	—
Feb 9, 2026	Dreyer ScottOfficer	Stock Award(Grant) at price 0.00 per share.	49.7K	—
Feb 9, 2026	Smith Thomas Brain M.D.Officer	Stock Award(Grant) at price 0.00 per share.	37K	—

13F

Investors Holding COLL

latest 13F filings of 29 followed managers

Investors holding COLL
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$49.5M	0.07%	1.37M	−7.0%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

COLL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

COLL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Collegium Pharmaceutical, Inc.

Seasonality · COLL

Insider Activity · COLL

Congress Trades · COLL

Investors Holding COLL

Investors Holding COLL

Congress Trades · COLL

Insider Activity · COLL

Seasonality · COLL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Collegium Pharmaceutical, Inc.

Financial Snapshot

Earnings & Dividends

News